SFC Energy AG

SFC Energy AG

19.01
USD
-0.81
(-4.09%)
0.94EPS
24.27P/E
401.19MMarket Cap
Apr 01Next Earn

Q3 FY2026 · Earnings Call TranscriptNovember 11, 2026

Operator

Ladies and gentlemen, welcome to the SFC Energy AG publication of the quarterly report Q3 2026 conference call. I'm Sergen, the Chorus Call operator.

I would like to remind you that all participants will be in listen-only mode, and the conference is being recorded. The presentation will be followed by a Q&A session.

You can register for questions at any time by pressing * and 1 on your telephone. Operator assistance, please press * and 0.

The conference must not be recorded for publication or broadcast. At this time, it's my pleasure to turn over to Dr.

Peter Podesser, CEO. Please go ahead, sir.

Dr. Peter Podesser

Thank you very much, Sergen, for the kind introduction. Good morning, ladies and gentlemen.

Good morning, everybody, and thanks for joining us, and welcome again after the recent preliminary number publication now to us leading you through the Q3 final numbers, as well as the 9-month results. It's a pleasure for Daniel and myself to lead you through this and naturally also being available for the Q&A session afterwards.

We're looking at a very good 9 months and an extraordinary quarter here in Q3 with first time surpassing 50 million revenue here in our company's history in a quarter and also unprecedented levels of of profitability. Let me shed some more light on especially the top-line development, and Daniel will lead you through, I'd say, the earning structure.

There's no secret, and it is naturally known to all of you, we had a strong push here and a dynamic momentum in the business driven by strong increase of the sales in our defense business, particularly also a successful completion of our first program here in Ukraine on time, I think, also meeting the expectation of our users as per their direct feedback. With this also naturally a a favorable product mix.

At the same time, I think we must not neglect with all the happiness on on how we develop in this part of the business, we must not neglect the solid development also in the other parts of our business. Looking at at some of the numbers, I think we're seeing strong demand and also demonstrate scalability of the business model and therefore also then the overproportional momentum in in in in the development of profitability.

We see a 29% growth here in revenues over the first 9 months, but at the same time, we see adjusted EBITDA rising more than threefold and EBIT more than fivefold, looking into this in a minute here together with Daniel. Just some background also on those developments here on the defense side, especially in the Ukraine, what we think as what we see is a confirmation by this program here of a unique suitability of the technology for a changed nature in modern warfare.

We get this direct feedback here from users also in my last trip also to to to see the users, meet the users in Ukraine recently. We learned that the demand here for off-grid and reliable electrical energy in the field is increasing at significant pace as at an enormous rate, I would say.

The use is for connectivity, naturally, still mobility, one of the drivers, and here most of it unmanned and electrical, sensor technology in the field, sensors deployed in the field, but then also traditional uses like communication. What we do with our fuel cell-based hybrid solutions, we enable a more agile, easy to deploy, longer lasting, and yeah, difficult to detect energy supply.

This again leads to longer mission duration, reduced logistical efforts, and I would say, the most important USP that we get mirrored back is higher safety for for the users by non-detectability. This naturally helps us to to to, I'd say, work on the continuation of the programs in Ukraine.

We are in the midst of building up the service and support structure there on on on on two locations. We are building up 24/7 support as we speak in order to also support the further business development here in the country.

It is also at the same time a reference to for for our international business, and I think we're making use of this. Just recently, we were also able to publish our collaboration in in the United Arab Emirates with EDGE, the leading defense and technology supplier there, and we're working also on programs in the States, as well as our OEM projects here in Europe, some of you might be also aware of.

This as a background here to the defense part of it. At the end, looking at where we end up in Q3, I think it is also the the logical impact here on our segmental development with, let's say, Clean Energy being the driving force of growth.

In the first 9 months, the segment revenue increased by 44% to 103.35 million compared to 71.5. Naturally here, it is also driven by the defense part of the business.

On a segmental level, the defense part, the the the the defense part now represents here at the 9-month level 46% of the segmental revenue, and on group's level, 36%, which is a significant increase. Also with this, we have about three-quarters, more than three-quarters, 77% of the total revenue coming out of Clean Energy.

Still Clean Power, yeah, we expected a a a a result as we have it. We knew we had a a a a weak outlook here from one of our largest customers out of the Netherlands leading to a slightly lower result than last year in this part of the business.

At the same time, we're seeing here, as mentioned, a favorable also gross margin development, which Daniel will look into with you together. If we look into the order intake, yes, we are below the levels we started into the year, and we are also below the level of of the the mid-year numbers, but this is definitely not a surprise.

With the accelerated execution here on the shipments to Ukraine, yeah, we had in this quarter a a negative or in the in the third quarter a negative book-to-bill, again, not a surprise, but still we're seeing very active order intake in Q3 here out of the other parts of the business. Expectations here for the end of the year, for Q4, but as also Q1, we expect some significant programs and orders to close.

We also want to draw your attention to the fact that there is a significant part of our business in the civilian fuel cell business, all what we do in CCTV, civilian surveillance here, in total accounting for about 1/3 of of the business, and also oil and gas shows a very good visibility here over the next quarters that will also contribute to an increase of backlog, not just by year-end, but especially also then looking into 2027. We feel also confident that this will be a good basis for growth going along into 2027.

With this, I think on the top line, I don't want to do any more repetition and handing over to Daniel leading you through the final earnings numbers here for Q3 and the first 9 months.

Daniel

Thank you, Peter. Good morning, everybody.

Thank you for joining our call. Let me go straight to the gross profit and the gross margin.

The gross profit margin has increased significantly compared to the prior year. We are looking at 48%, which is 8.5 percentage points above what we've seen in the prior year.

The development, however, differs between the segments. You have already seen in our report that we had a strong increase in the segment Clean Energy on the gross margin with a gross margin of 45 44.4% and a slight decline in the gross margin of the Clean Power Management segment, which is at 29.2%.

One of the reasons, and Peter already touched on that, that the product mix in Clean Power Management shifted a little bit. Overall, we consider the group's gross margin to be at a very good level with, again, some upside potential in the segment Clean Power Management, where the revenue shifts in product mix towards the lower-margin frequency converters for the oil and gas industry weighted on the gross margins.

Looking at our operating expenses, let me touch on some key topics with regards to one-offs that we've shown in the first 9 months. Overall, the operating expenses increased by 7.3% in the first 9 months to €39.1 million, which compared to €36.5 million in the prior year.

However, there were some nonrecurring negative effects resulting, first of all, an impairment of capitalized R&D expenses amounting to €2.2 million, which are recognized in the R&D expenses and subsequently in the depreciation, amortization. Then we have a consultancy expense of approximately €1.3 million and in connection with closing the Ukraine transaction, which are recognized in the sales and marketing expenses.

Going into the operating expenses and starting with the R&D expenses, these showed the highest increase compared year on year. On the one hand, the capitalization rate of the development costs was 14%, which is below what we've seen in the prior year where the levels were 60%.

On the other hand, and I mentioned that, the R&D expenses include the impairment of €2.2 million for the capitalized development project. Sales expenses showed the second highest increase driven by the consultancy expense and provisions for the Ukraine order, which I mentioned, amounted to €1.3 million.

General and administrative expenses were slightly below the prior-year level. Foreign exchange gains and losses were balanced in the first 9 months, resulting in a slight net gain from FX exchange rates.

You'll see in the impairment loss on financial assets an expense of or we include an expense of €900,000. This expense is driven by a bad debt provision of roughly €1 million for a single trade account receivable.

It is a specific case-related item and not an indication of a broader deterioration in the quality of our receivables portfolio. If we would exclude this one-off effects of roughly 4.5 million in total, then our operating expenses would have decreased by approximately 5% to €34.7 million compared to €36.5 million.

This shows that the cost basis is under control and that the increase in this operating expenses is driven exclusively by these nonrecurring items. As we said, we are not adjusting our EBIT or EBITDA for for these nonrecurring items.

However, we're adjusting our EBIT and EBITDA, as we've done in the past, for the expenses related to the stock-based long-term incentive and compensation of senior management and board, as well as for transaction expenses relating to the M&A activity and the investments that we made this year in Oneberry as well as Sequence. Adjusted, the adjusted EBITDA for these expenses amounted to €33.7 million, more than tripled compared to the previous year's the period where the adjusted EBITDA was €10.8 million.

This then translates in an increase of the EBITDA margin to 25.4%, coming from 10.5% in 2025. The increase is due and strong due to the strong gross margin expansion.

I meant I mentioned the gross margin increased by 8.4 percentage points, mainly driven by the Clean Energy segment where the revenue growth and the favorable product mix with a high share of defense revenue had a very positive effect on margins, and to some extent, on the pronounced operating leverage effect. Revenues grew by 29.3%, while operating expenses only increased by 7.3%, which then if we if we look at the one-off effects, then operating expenses decreased by 5%, which is not reflected in the adjusted EBITDA, and that is with the reason for the increase in our adjusted EBITDA.

Depreciation and amortization, you'll see a total of €8 million, which seems to be and really is significantly higher from the €5.8 million we had in the previous year. The increase is driven by the amortization of the intangible assets, which rose to €4 million.

Intangible assets is mostly capitalized R&D, and within the capitalized R&D, as I mentioned, we have the impairment of the capitalized development costs of €2.2 million. Excluding this one-off effect, D&A would have been at a level of €5.8 million, i.e., that is pretty much on the level of the prior year.

Around 30% of the D&A, depreciation and amortization, is IFRS 16-related. The amortization for IFRS 16 is €2.4 million.

That compares to €2.3 million in the previous year. The slight increase increase is mostly due to a new site and building that we have in the Netherlands.

Outlook, you will see that the D&A will not significantly increase. This brings us to the adjusted EBIT.

Adjusted EBIT amounted to €25.7 million, and that is an increase it's more than fivefold compared to what we've seen in the previous year. Looking quickly in CapEx, cash flow, outflow from investing investing activities, also there, you've seen that the cash flow from investing activities was €6.8 million in the first 9 months.

That compares with the €2.6 million in the first 9 months 2025, and that increase is entirely driven by two nonrecurring items. The first item is the 15% investment in Oneberry, which we closed in the first quarter of this year.

All of you who've been on the previous quarterly calls know that the amount is €3.4 million. The purchase price for the assets of Sequence, which we closed in the second quarter, which was roughly €1 million.

Sorry, third quarter, that was just €1 million. If you exclude those one-off items, the cash outflow from investing activities would have been €2.5 million, which compares to €2.6 million in the previous year, and that's pretty much on the level we've seen in the last year.

Of this underlying outflow, €1.5 million relates to capitalized development costs, and the investment in property, plant, and equipment amounted to €1.3 million, which again is pretty much on the level what we've seen in the previous years. This investment in PP&E is mainly driven and related to expansion and automation of our business operations.

Cash position, €70.3 million at the end of the third quarter. Looking at our financial debt, €3 million at the end of the third quarter, which brings us to a net cash position of €60.3 million, which is at a very healthy level.

Equity apparently increased to €50.8 million, and that is driven by a very strong net profit of €14.3 million at the first 9 months. That then translates into a stable equity ratio at 72.0%.

Cash flow: operating cash flow before change in net working capital, a very solid €32.3 million, coming from a low €10.5 million in the prior year. That that very strong increase really reflects the strong operating performance characterized by revenue growth and the margin expansions.

Net working capital, we saw a slight decrease versus year-end level of €3.4 million. That that that decrease contributed to an inflow of €3.5 million in the first 9 months, compared to the high outflow that we have in the prior year of 21.5 million.

The swing in the net working capital is €24.9 million. The trade receivables were the main driver in net working capital releasing €6.2 million of cash compared to year year-end.

The trade receivables stood at €41.1 million, down from €47.9 million at year-end. Days of sales outstanding on a last 12-month sales basis decreased to 97 days compared to 122 days at the year-end.

Inventories increased slightly by €2.9 million. This is far less than what we've seen in the prior-year period where inventory increased for €10.3 million.

The inventory buildup has slowed significantly, and inventory stood at €39.4 million, comparing to 35.3 million at year-end. Like I said, it is an increase.

We still increased the inventory days to 198 days compared to 152 days at the year-end, which really remains at the higher end, and we continue really to make substantial efforts to optimize our inventory levels. Provision provided a cash inflow of €2 million, partly offset by an increase in short-term receivables of €1.5 million.

Trade payables had a slight negative effect on our cash flow of €700,000. That compares to €2.8 million in the prior year, and that decreased the days payable outstanding from 66 days at year-end to 6 sorry, from 66 days at year-end to 63 days at year-end.

The net working capital as a share of revenue improved to 32% from 38% at year-end, which is driven, again, to some extent, by the optimization of our net working capital, but also by the strong revenue growth. Tax payment that we had was 2 million.

If you get good results, then tax payments unfortunately or fortunately also increase. That brings to us to a cash flow from operating activities to €33.7 million.

That compares to the negative amount the negative number from last year of €12.4 million. A solid improvement of €46.1 million.

Again, the strong improvement had two components: strong operating cash flow and the net working capital which turned from a cash outflow to an inflow. Cash flow from investing activities, I already mentioned that, €6.8 million, as discussed.

The increase was driven by those two nonrecurring items, the investment in Oneberry as well as the acquisition of the Sequence assets. Cash flow from financing activity amounted to -€3 million.

The largest portion of that cash flow is really related to IFRS 16 sorry, lease payments that we're having. That brings us to the free cash flow operating plus investing cash flow of €26.8 million.

The change in cash was €23.9 million, leaving us with a very solid cash position at the end of the 9 months. With those details, I'll turn it back to Peter.

Dr. Peter Podesser

Thank you very much, Daniel. On the forecast, there is not so much of a change to what we've published here on the 29th of October, obviously, here when we raised our guidance.

We continue to see favorable and dynamic demand here across the business, leading to also a noticeable increase of the backlog as of today compared to quarter-end here, the numbers we discussed before. At the same time, yeah, we see a project pipeline that will lead to, and we expect it to lead to, larger contracts to be closed here till year-end, but also then, especially also in Q1.

Looking at the numbers, on the revenue side, we stay with the corridor here, 166 to 175 million from a very recent, I think, assessment. We are seeing a realistic midpoint of the range here as the target figure as of today.

There might be some last-minute accelerated projects also coming in here, changing this to the upper half, but for the time being, I think the midpoint of the guidance here is a good target number. Adjusted EBITDA, the range lifted up on the 29th of October, 36 to 38 unchanged, and also on the EBIT, the new range out since 10 day, more or less 10 days, 25.5 to 27.5.

What do we expect here for Q4? For Q4, being on the 11th of November today, we are seeing a very comparable product mix and also in size compared to the first quarter, so much more dominated here by civilian products again, as expected.

We also expect here therefore a different also contribution to earnings compared to Q3 and Q2 dominated here by the increase here of the defense part of the business. We are also planning for additional expenses here for our ERP projects.

We had to delay some of the activities also within this project here in the last couple of weeks. Then we are also naturally making use of our solid balance sheet and cash position to do targeted investments into business development.

We mentioned this before, we do this right now in Ukraine, but we also started the activities or expanding the activities here in the Middle East. This all is naturally laying the basis here for expanding business, especially also in 2027 and the years thereafter, clear investment here into further profitable growth.

With this, I would like to close it at this point in time, a little faster than usual, as said, we have some of the numbers already out, and give us more time for our Q&A and then answering your questions. Thank you very much.

Handing over to Sergen.

Operator

Ladies and gentlemen, we'll now begin the question-and-answer session. Anyone who wishes to ask a question may press * and 1 on their telephone.

You will hear a tone to confirm that you have entered the queue. If you wish to remove yourself from the question queue, you may press * and 2.

Anyone with a question may press * and 1 at this time. The first question comes from Karsten von Blumenthal from First Berlin Equity Research.

Please go ahead.

Karsten von Blumenthal

Good morning, Peter. Good morning, Daniel.

At first, a question regarding the defense share in the business. The line was a bit shaky, just to fix it, Peter, is it right you said in the first 9 months defense had 46% of the segment and 36% of the group?

Is that right?

Dr. Peter Podesser

Yes.

Karsten von Blumenthal

Thanks. Perfect, then I understood it right.

There is hardly anything weak to find. The only thing that strikes me is the US business is particularly weaker than last year.

I think in the last conference call, you mentioned a sales initiative in the US, but perhaps you could comment on the weaker US figures compared to last year.

Dr. Peter Podesser

Yes, absolutely. I think a continued focus here of our organic growth is building out our own sales organization here, feet on the ground across the nation.

I think we are now completing the team by covering the last white spots we are still having there. Also, consolidated management team for North America is in place here, covering our US and Canadian activities.

Maybe a data point that, I'd say, gives me a lot of confidence that we are on the right track, if you look at the focus area of the civilian business, that is the CCTV business, civilian security, we experienced a weaker development here with our lead customer there over a period of time already and reported this, there's strong competition in the market. When we look at our customer base, the diversification, I think, is really showing good results.

While we started into 2025 with a handful of CCTV customers, 5 customers at that time, we are right now looking at 18 repeat customers in CCTV. We are seeing 10 new logos also in our piloting stage.

We are continuing a very focused, let's say, sales campaign here. Just some data points to this: we're doing calling activities with more than 1,200 leads we started this, and we drilled it down then to 41 qualified customer contacts, apart from all, let's say, direct sales activities.

Still, the adoption time for our technology, naturally, we know this, is also in the US, it is an 18 to 24-month adoption period. Although we have a significantly broadened customer base, the volume development is still, let's say, behind the expectations.

We calibrated our expectations for this year, and this is also reflected in our guidance. As being right now in the planning for next year, naturally, the broader customer base will be and should be the basis here for again double-digit organic growth, which is the clear expectation and plan for 2027.

It's organic sales growth out in the field with, let's say, all naturally support here by communication, but at the end, it's still a technical sale. You still have to go there, and people want to see the fuel cells operate and survive properly during a winter and reducing, let's say, their operational cost by longer service cycles, less service visits, lower fuel consumption, all what you know.

At the end, yes, this is an area of real attention, including, let's say, us here from the executive team being on site, being in the country really on a very regular base. We should not neglect the defense activities.

We restarted after the US forces revised their 10-year-old decision not to take new technologies here for off-grid power apart from diesel-based and fuel-based generators. We were at AUSA.

We are, I think, at a good stage to enter into what they call a CRADA activity, a collaborative development program here with the armed forces, and that's the reentry into the defense market, also contributing slightly to the expected sales increase in 2027. That's the plan.

Sorry for the long answer here, but it is a focus area for us right now.

Karsten von Blumenthal

No, thank you very much for that. That is very helpful.

One last question from my side, Peter. At the beginning, you mentioned the USP of your power solutions for defense business.

Do you see any competition there? As far as I know, you are the only one with a NATO stocking number for fuel cell-based supply solutions.

Is there anything out you see as a competition, or have you still the field for you?

Dr. Peter Podesser

I can, I'd say, confirm we are the one that has all the qualifications formally, but then at the same time, it's also about being combat-proven. I think this was the massive milestone taken over the last couple of quarters here in Ukraine with our activities yielding to the volumes that we're seeing right now.

At the end, I think we also have to look back realistically, the defense part of this business was not en vogue here to call it this way for quite some time, and I think we were the only one staying in and continuing to invest into a proper product offering. This gives us a head start, I would say, of a couple of years.

Karsten von Blumenthal

Perfect. Thank you very much for answering my questions.

Dr. Peter Podesser

Thank you.

Operator

As a reminder, if you wish to register for a question, please press * followed by a 1 on your telephone. There are no more questions at this time.

I would now like to turn the conference back over to Dr. Peter Podesser for any closing remarks.

Dr. Peter Podesser

Surprisingly not. We are apparently addressing all questions for the time being, but as you all know, we're here at your disposal here for the direct communication.

Reach out to Susan, Daniel, or myself, and we are happy to address any type of question and also lead you through the details here of the results and the outlook. With this, we are closing a quick call, and thank you very much for your attention.

Operator

Ladies and gentlemen, the conference is now over, and you may now disconnect your lines. Goodbye.